← Back to Home

Duchenne Muscular Dystrophy Gene-Editing Trial Published: Behind the Molecular Effects, a Boy’s Death Raises Safety Concerns

HG302 showed evidence of gene editing and protein expression in muscle, but whether it can deliver lasting benefits remains unproven. A fatal immune reaction in the four-participant trial makes dose selection and disclosure of safety information unavoidable questions.

By SURL BioNews

For patients with Duchenne muscular dystrophy (DMD), who progressively lose muscle strength, repairing the disease-causing gene holds hope of changing the course of the disease. However, results from the human trial of HuidaGene’s experimental therapy HG302 show that getting gene-editing tools to work in muscle remains some distance from a safe and effective treatment. The study, recently published in *Cell*, documented molecular activity as well as the circumstances of a boy’s death from a treatment-related serious adverse event.

*Nature* reported on October 27 that although the trial confirmed editing in some copies of the target gene, the treatment benefits were limited. According to the study summary released by HuidaGene the same day, HG302-01 was an investigator-initiated, first-in-human trial in which four boys who could still walk received a single intravenous infusion at doses of 5.0×10^13 or 1.0×10^14 vector genomes per kilogram of body weight.

DMD results from mutations in the DMD gene that leave muscles without enough functional dystrophin, causing progressive loss of strength. HG302 uses an in vivo CRISPR/Cas gene-editing strategy aimed at restoring expression of this protein. The company said post-treatment muscle biopsies showed editing at the target site and detectable protein; however, these tissue changes cannot yet directly answer whether the children can retain their ability to walk over the long term.

Signals of functional improvement also require cautious interpretation. The company reported that two participants who completed 12 months of follow-up improved on an ambulatory function scale and the six-minute walk test; *Nature*, meanwhile, described the overall treatment benefits as limited. These exploratory results come from only a small number of participants and cannot establish efficacy or represent outcomes for everyone who received treatment.

The gravest finding concerned the fourth participant. According to the investigation released by the company, he developed acute respiratory distress syndrome after receiving the high dose, accompanied by marked complement activation and systemic inflammation, and ultimately died. Complement is part of the immune defense system; this event underscores that severe immune reactions during systemic delivery using adeno-associated virus (AAV) vectors may still exceed what existing preventive measures can control. The available data are also insufficient to attribute the risk solely to the gene-editing tool itself.

Publication of the paper also filled in a timeline of information disclosure that had come under scrutiny. In a statement dated August 5, 2026, HuidaGene confirmed that the death occurred in August 2025 and that the investigation findings, including postmortem analyses, had been submitted for peer review in January 2026. STAT reported in August that the company released an update only after sustained investigation and repeated questions from the outlet; the report also questioned why the trial proceeded to a higher dose when benefits for the first two patients remained unclear. The company said the event had been reported within applicable deadlines through hospital ethics and research oversight procedures. That statement and the timing of public disclosure concern different levels of transparency.

Trial dosing is now complete, and the three surviving participants continue to undergo long-term safety follow-up. Publicly accessible information still consists mainly of the company’s summary and news reports and remains insufficient for a full assessment of individual patients’ benefits and risks. The central questions left by these results are how to identify a delivery dose the human body can tolerate while achieving sufficient editing, and how to establish monitoring methods that can better provide early warning of severe reactions. Both molecular effects and clinical safety must be demonstrated.

References

  1. Nature
  2. HuidaGene Therapeutics
  3. HuidaGene Therapeutics
  4. STAT